Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Agai... (tolerated provides the expected immediat...)

Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies

Date:1/3/2008

tolerated, provides the expected immediate passive neutralizing activity, and that it can be safely administered in combination with a rabies vaccine without interfering with the vaccine's ability to induce an active immunity.

Under the terms of the agreement, Crucell will continue to perform the development activities and will manufacture the final product. Crucell will receive a payment of EUR 10 million following the execution of the agreement and would be eligible for milestone payments of up to EUR 66.5 million.

About rabies:

Rabies is an acute viral encephalitis transmitted from animal to animal or from animal to human by exposure to saliva. Virus in saliva attaches to peripheral nerve endings and progresses to the brain. All mammalian species are believed to be susceptible. Dogs are a major reservoir of human rabies. They are responsible for most incidences of bites.

Rabies vaccination by Louis Pasteur was an important step in the history of vaccine when, in 1885, Joseph Meister, who had been bitten by a rabid dog, was successfully treated by successive inoculations during a 10-day period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The Company's heritage, to crea
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
4. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
5. Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine
6. Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine
7. Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
11. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers

Post Your Comments:

Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Agai...(tolerated provides the expected immediat...),Health